Monopar Therapeutics Inc
MNPR80.950USD
+0.190+0.24%
Close 11/07, 16:00（ET）Quotes delayed by 15 min
496.02MMarket Cap
LossP/E TTM
More Details of Monopar Therapeutics Inc Company
Monopar Therapeutics Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for cancer patients. The Company is building a drug candidate pipeline through in-house development as well as the licensing and acquisition of therapeutics in late preclinical and in clinical development stages. The Company has several compounds in development, which include MNPR-101-Zr, MNPR-101-RIT, Camsirubicin and MNPR-202. MNPR-101-Zr is a clinical-stage urokinase plasminogen activator receptor (uPAR)-targeted radio diagnostic imaging agent. MNPR-101-RIT is a late preclinical stage radiotherapeutic for advanced cancers. Camsirubicin is an analog of doxorubicin which has been designed to reduce the cardiotoxic side effects generated by doxorubicin while retaining effective anti-cancer activity. MNPR-202 is an early-stage analog of camsirubicin designed to potentially treat doxorubicin- and camsirubicin-resistant cancers.
Monopar Therapeutics Inc Info
Ticker SymbolMNPR
Company nameMonopar Therapeutics Inc
IPO dateDec 19, 2019
CEODr. Chandler D. Robinson, M.D.
Number of employees16
Security typeOrdinary Share
Fiscal year-endDec 19
Address1000 Skokie Blvd Ste 350
CityWILMETTE
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code60091-1146
Phone18473880349
Websitehttps://www.monopartx.com/
Ticker SymbolMNPR
IPO dateDec 19, 2019
CEODr. Chandler D. Robinson, M.D.
Company Executives of Monopar Therapeutics Inc
Name
Name/Position
Position
Shareholding
Change
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
79.42K
+8.10%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
6.17K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Mr. Vu Quan
Mr. Vu Quan
Chief Financial Officer, Principal Accounting Officer
Chief Financial Officer, Principal Accounting Officer
--
--
Dr. Patrice P. Rioux, M.D., Ph.D.
Dr. Patrice P. Rioux, M.D., Ph.D.
Acting Chief Medical Officer
Acting Chief Medical Officer
--
--
Mr. Andrew J. Cittadine
Mr. Andrew J. Cittadine
Chief Operating Officer
Chief Operating Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Dr. Chandler D. Robinson, M.D.
Dr. Chandler D. Robinson, M.D.
Chief Executive Officer, Director
Chief Executive Officer, Director
79.42K
+8.10%
Dr. Christopher M. (Chris) Starr, Ph.D.
Dr. Christopher M. (Chris) Starr, Ph.D.
Executive Chairman of the Board
Executive Chairman of the Board
16.05K
--
Ms. Lavina Talukdar
Ms. Lavina Talukdar
Independent Director
Independent Director
14.00K
--
Ms. Kim R. Tsuchimoto
Ms. Kim R. Tsuchimoto
Director
Director
11.49K
--
Mr. Arthur J. Klausner
Mr. Arthur J. Klausner
Independent Director
Independent Director
6.17K
--
Mr. Raymond William (Bill) Anderson
Mr. Raymond William (Bill) Anderson
Independent Director
Independent Director
5.37K
--
Revenue Breakdown
No Data
No Data
By Business
By Region
No Data
Shareholding Stats
Updated: Tue, Aug 19
Updated: Tue, Aug 19
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
Janus Henderson Investors
17.73%
Gem Pharmaceuticals LLC
9.24%
Adage Capital Management, L.P.
9.06%
RA Capital Management, LP
7.73%
AstraZeneca PLC
5.86%
Other
50.37%
Shareholders
Shareholders
Proportion
Janus Henderson Investors
17.73%
Gem Pharmaceuticals LLC
9.24%
Adage Capital Management, L.P.
9.06%
RA Capital Management, LP
7.73%
AstraZeneca PLC
5.86%
Other
50.37%
Shareholder Types
Shareholders
Proportion
Investment Advisor/Hedge Fund
20.88%
Corporation
19.21%
Hedge Fund
14.05%
Venture Capital
7.73%
Investment Advisor
5.43%
Individual Investor
4.80%
Research Firm
0.19%
Pension Fund
0.12%
Bank and Trust
0.06%
Other
27.52%
Institutional Shareholding
Updated: Wed, Oct 1
Updated: Wed, Oct 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q3
99
3.34M
50.46%
+135.23K
2025Q2
76
5.07M
82.91%
-355.61K
2025Q1
72
5.03M
83.96%
+455.96K
2024Q4
54
4.84M
79.28%
+1.76M
2024Q3
40
1.90M
50.69%
+25.14K
2024Q2
43
1.96M
52.51%
+123.52K
2024Q1
46
1.91M
52.92%
+136.66K
2023Q4
44
1.88M
67.20%
+125.61K
2023Q3
42
1.87M
67.45%
+153.91K
2023Q2
38
1.84M
66.75%
+138.58K
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
Janus Henderson Investors
1.17M
17.73%
+37.96K
+3.35%
Jun 30, 2025
Gem Pharmaceuticals LLC
611.08K
9.24%
--
--
Apr 04, 2025
Adage Capital Management, L.P.
599.20K
9.06%
--
--
Jun 30, 2025
RA Capital Management, LP
511.21K
7.73%
--
--
Jun 30, 2025
AstraZeneca PLC
387.33K
5.86%
+387.33K
--
Oct 23, 2024
Tactic Pharma LLC
272.03K
4.11%
-550.23K
-66.92%
Sep 24, 2025
The Vanguard Group, Inc.
86.49K
1.31%
+31.25K
+56.59%
Jun 30, 2025
BlackRock Institutional Trust Company, N.A.
183.97K
2.78%
+175.22K
+2003.49%
Jun 30, 2025
Point72 Asset Management, L.P.
104.02K
1.57%
-64.14K
-38.14%
Jun 30, 2025
Adar1 Capital Management LLC
100.97K
1.53%
+200.00
+0.20%
Jun 30, 2025
View more
Related ETFs
Updated: Thu, Nov 6
Updated: Thu, Nov 6
Name
Proportion
iShares Micro-Cap ETF
0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
0.05%
iShares Russell 2000 Growth ETF
0.02%
Proshares Ultra Russell 2000
0.01%
Global X Russell 2000 ETF
0.01%
ProShares Hedge Replication ETF
0.01%
ProShares UltraPro Russell2000
0.01%
iShares Russell 2000 ETF
0.01%
Avantis US Small Cap Equity ETF
0%
iShares Micro-Cap ETF
Proportion0.05%
Goldman Sachs ActiveBeta US Small Cap Equity ETF
Proportion0.05%
iShares Russell 2000 Growth ETF
Proportion0.02%
Proshares Ultra Russell 2000
Proportion0.01%
Global X Russell 2000 ETF
Proportion0.01%
ProShares Hedge Replication ETF
Proportion0.01%
ProShares UltraPro Russell2000
Proportion0.01%
iShares Russell 2000 ETF
Proportion0.01%
Avantis US Small Cap Equity ETF
Proportion0%
Dividend
A total of
0.00
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
No Data
Stock Split
Date
Type
Ratio
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Date
Type
Ratio
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
Aug 09, 2024
Merger
5→1
